top of page
For most cost-effective consulting services:
Click here
Home
All News
Pharma
US FDA Approvals
North America
China Drug Approvals
Japan Drug Approvals | Healthcare
India Drug Approvals
APAC - Drug Approvals
LACAM
Europe
Canada Drug Healthcare News
Brazil - Drug approvals
EMA News
APAC
Therapy News
Immunology
Neurology
Oncology
Kidney Diseases
Cardiovascular
Infections_Vaccines
Metabolic Diseases
Women Health
Healthcare News
US Healthcare News
US Payer News
Europe Healthcare News
NICE Assessment Outcomes
G-BA Assessment Outcomes
APAC - Healthcare News
Lacam Healthcare News
Healthcare Policies
Conferences
About
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
FDA Approves Jideytro for Previously Treated ROS1 Positive Non Small Cell Lung Cancer
Badari Andukuri
2 days ago
Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter
Badari Andukuri
4 days ago
Aetna Survey Highlights Evolving Payer-Provider Confidence Landscape | iPharmaCenter
Badari Andukuri
Jul 15
FDA Approves KEYTRUDA-Padcev Combo as First Perioperative Standard for Muscle-Invasive Bladder Cancer
Badari Andukuri
Jul 11
Medicare GLP‑1 Bridge Program: Eligibility, Costs, and Drug Details | iPharmaCenter
Badari Andukuri
Jun 25
FDA Clears Sanofi’s Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes | iPharmaCenter
Badari Andukuri
Jun 17
Baxfendy (baxdrostat) Approved in the US as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension | iPharmaCenter
Badari Andukuri
May 18
Foundayo (orforglipron) Wins FDA Approval as First Anytime GLP‑1 Tablet for Weight Loss | iPharmaCenter
Badari Andukuri
Apr 8
Johnson and Johnson approved Tecvayli plus Darzalex Faspro for 2L multiple myeloma | iPharmaCenter
Badari Andukuri
Mar 7
FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter
Badari Andukuri
Feb 7
AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back | iPharmaCenter
Badari Andukuri
Jan 31
Amlitelimab meets primary endpoints in Phase 3 atopic dermatitis trials, enabling Sanofi regulatory submissions | iPharmaCenter
Badari Andukuri
Jan 26
FDA clears one‑minute subcutaneous mosunetuzumab for heavily pretreated follicular lymphoma | iPharmaCenter
Badari Andukuri
Jan 23
Lilly’s Sofetabart Mipitecan Wins FDA Breakthrough Tag in Tough‑to‑Treat Ovarian Cancer | iPharmaCenter
ipharmaservices
Jan 22
Sun Pharma Launches UNLOXCYT in the U.S. for Advanced Cutaneous Squamous Cell Carcinoma
ipharmaservices
Jan 17
Boehringer Ingelheim Bolsters Pulmonary Fibrosis Portfolio with Jascayd Approval for Progressive Cases
Badari Andukuri
Dec 23, 2025
FDA Clears Wegovy Pill as First Oral GLP-1 for US Weight Management
ipharmaservices
Dec 23, 2025
FDA Clears Breyanzi as the First CAR T‑Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma in the US | iPharmaCenter
Badari Andukuri
Dec 5, 2025
US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension
ipharmaservices
Dec 4, 2025
FDA Approves Jaypirca for Relapsed or Refractory CLL/SLL Previously Treated with Covalent BTK Inhibitors | iPharmaCenter
ipharmaservices
Dec 4, 2025
bottom of page
